Macular Hole Progression following Ocriplasmin Intravitreal Injection. (14th December 2014)

• Record Type: Journal Article
• Authors: Casswell, Edward; Fernandez-Sanz, Guillermo; Mitry, Danny; Luk, Sheila; Zakir, Rahila
• Other Names: Bialasiewicz Alexander A. Academic Editor.
• Is Part Of: Case reports in ophthalmological medicine. Volume 2014(2014)
• Publication Date: 2014-12-14
• Subjects: Ophthalmology -- Periodicals; Eye -- Diseases -- Periodicals; Ophthalmology; Eye Diseases; Eye -- Diseases; Ophthalmology; Electronic journals; Periodicals; Periodicals; Case Reports; Fulltext; Internet Resources; Periodicals; 617.7
• DOI: 10.1155/2014/403461
• Languages: English
• ISSNs: 2090-6722

Abstract

Abstract : Ocriplasmin is a protease which has been approved for the treatment of symptomatic vitreomacular adhesion (VMA). A 63-year-old presented with blurred vision in the left eye and a best corrected visual acuity of 6/18. Optical coherence tomography revealed VMA with an underlying macular hole and she subsequently underwent a left intravitreal ocriplasmin injection. One week after the injection, VMA had been released but with enlargement of the macular hole and a drop in her BCVA to 6/60. This persisted at 1 month after the injection. It is important to warn patients that ocriplasmin may lead to an enlargement of their macular hole with resultant loss in visual acuity.